One-Two Punch: Novel Drug Pairing Could Beat Pancreatic Cancer
|
UC San Diego researchers Herve Tiriac and Andrew Lowy have found that a combination of drugs outperformed other treatments in human and mouse models of pancreatic cancer; they now urge a clinical trial. Read More»
|
|
|
Scholarships Available for the 32nd Annual JAX Short Course in Cancer
|
The Jackson Laboratory 32nd Annual Short Course on Experimental Models of Human Cancer will be held in Bar Harbor, Maine and virtually August 14–22, 2023. The Jackson Laboratory encourages students, post-doctoral fellows, and/or junior faculty from populations under-represented in the biomedical sciences (see NIH NOT-OD-20-031 for definition) to register. Moores' Dr. Varner, Dr. Cheresh, and Dr. Karin will take part in the course. Learn More»
|
|
|
July 14, 2023 | 3:00 p.m. PT
|
July 25, 2023 | 3:00 p.m. ET
Zoom
|
| |
NCI Cancer Prevention Fellowship Program
|
Applications for this postdoctoral fellowship program are open through August 1, 2023.
|
|
Applications for KL2 Mentored Career Development Award Now Open!
|
The ACTRI KL2 award is a mentored career development award that provides up to $120K toward salary, plus benefits, along with $25K per year in research funds. Successful applicants will receive up to 3 years of support. Applications for this program are open through August 15, 2023.
|
|
|
FEATURED FUNDING OPPORTUNITIES |
The goal of providing these Research Grants and Fellowships Programs is to identify and provide funding for innovative projects that exhibit the potential to make substantial contributions to cancer prevention and early detection. The Prevent Cancer Foundation defines cancer prevention as the “reduction of cancer incidence through research, education, and early detection.” Both Research Grants and Fellowships Programs will be awarded for 2 years at $50,000 per year, for a total of $100,000.
Deadline: Tuesday, July 11, 2023
|
The Department of Defense, Congressionally Directed Medical Research Programs (CDMRP), PRCRP award funds innovative basic, applied, and translational cancer research to support military service members, their families, and the American public for 20 cancer and disease topic areas. The PRCRP does not fund research in cancers that have a dedicated research program at CDMRP, which are breast, prostate, ovarian, lung, pancreatic, kidney, and melanoma. Although CDMRP does have a dedicated rare cancer program, the PRCRP can fund research on rare cancers or rare cancer subtypes for cancer topics that are topics named in the PRCRP program.
Deadline: Tuesday, July 25, 2023
|
This award will fund up to $500,000 for a research proposal featuring novel technology or approaches for target discovery or treatment in gastroesophageal cancer. Grantees will gain access to a supply of gastroesophageal cell lines, patient-derived organoids, and mouse models to facilitate research projects.
Deadline: Tuesday, August 1, 2023
|
This retention-focused, institutionally-supported program will support under-represented minority faculty members in submitting successful resubmissions of NIH K or R (or equivalent) grant applications. The goal of the SUSTAIN program is to increase the likelihood of successful proposal resubmission by providing protected time, grant writing training, and linkage to didactic, mentorship, and other resources, which are customized to the applicant. The SUSTAIN program provides 1–2 years of support at 50% of full-time salary (up to $60,000), which must be matched by the department and confirmed in a letter from the candidate’s Department Chair. The combined effort must enable a total of at least 75% research effort.
Deadline: Friday, September 1, 2023
|
|
|
Journal of Clinical Oncology
Rana R. McKay (Structural and Functional Genomics)
|
Immunity
Jack D. Bui (Hematologic Malignancies) and Enfu Hui (Hematologic Malignancies)
|
Gastroenterology
Shailja C. Shah (Cancer Control Program)
|
|
|
19-202: INTREPId (INTermediate Risk Erection Preservation Trial): A Randomized Phase II Trial of Radiation Therapy and Darolutamide for Prostate Cancer
|
PI: Tyler Seibert
NCT: NCT04025372
|
KT-US-982-5968: Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
|
PI: Dimitrios Tzachanis
NCT: NCT05041309
|
R3767-ONC-2055: A Phase III Trial of Fianlimab (AntiLAG3) and Cemiplimab Versus Pembrolizumab in the Adjuvant Setting in Patients with Completely Resected High-Risk Melanoma
|
PI: Gregory Daniels
NCT: NCT05608291
|
CF33-hNIS-002: A Phase I, Dose Escalation Safety and Tolerability Study of VAXINIA (CF33hNIS), Administered Intratumorally or Intravenously as a Monotherapy or in Combination with Pembrolizumab in Adult Patients with Metastatic or Advanced Solid Tumors (MAST)
|
SRK-181-001: A Phase I, Open-Label, Dose-Escalation, and Dose-Expansion Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of SRK181 Alone and in Combination With Anti-PD(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)
|
PI: Rana McKay
NCT: NCT04291079
|
|
|
COMMUNITY OUTREACH AND ENGAGEMENT |
Moores Members at the AACI Clinical Research Innovation Conference
|
Moores' Community Outreach and Engagement (COE) joined forces with the Moores Clinical Trials Office (CTO) this week at the 15th Annual Association of American Cancer Institutes Clinical Research Innovation (AACI CRI) conference in Chicago. Arcadia Cruz, PhD (CTO), who currently serves on AACI-CRI's steering committee, and Jesse Nodora, DrPH (COE) moderated and presented, respectively, during the session, "It Takes a Community: Overcoming the Barriers to Decentralized Trials.” Addressing problem-solving challenges to building a community network for cancer clinical trials and improved representation, the session highlighted the progress of COE and CTO partnered efforts to improve accrual of Hispanic patients to therapeutic trials (16% in 2013 vs. 21% in 2019) by implementing solutions derived from focus group outreach. Areas that remain a focus for research include barriers and facilitators to adequate informed consent and role of ethnicity, health literacy, culture and language in trial enrollment, and the opportunity for community-based participatory research to inform these ongoing efforts.
|
UCSD Health Equity Consortium Seminar
|
Please join Moores' Center for Health Equity and Education Research (CHEER) and COE on Friday, July 14 for the UCSD Health Equity Consortium Seminar. Dr. Marc Emerson will deliver a presentation titled, "Addressing Cancer Care Inequities in Black and American Indian / Alaskan Native Populations." Dr. Emerson is an Assistant Professor of Epidemiology at UNC Chapel Hill and is Diné (Navajo) and Jemez from the Navajo Nation. The seminar will take place in the Moores Comer Commons. This seminar is free, in-person, and intended for academic researchers, clinicians, cancer center staff, and native-focused organizations/groups. Please contact Elizabeth Duran (e2duran@health.ucsd.edu) for information.
|
|
|
Manage your preferences | Opt Out using TrueRemove™
Got this as a forward? Sign up to receive our future emails.
View this email online.
|
3855 Health Sciences Drive MC 0698 | La Jolla, CA 92093 US
|
|
|
This email was sent to sjchristie@ucsd.edu.
To continue receiving our emails, add us to your address book.
|
|
|
|
